A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants

A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Danicamtiv in Healthy Japanese and Caucasian Participants

The purpose of this study is to assess the safety, tolerability, and single-dose pharmacokinetics of danicamtiv in healthy Japanese and Caucasian participants.

Inclusion Criteria:

• Body mass index between 18 and 30 kilograms/meter squared inclusive, at the screening visit.
• Japanese participants must be of Japanese descent (both biological parents are ethnically Japanese).
• Caucasian participants must be of European or Latin American Caucasian descent.
• A female participant is eligible to participate if she is a woman of nonchildbearing potential as defined in the protocol.
• Males who are sexually active with woman of childbearing potential must agree to follow protocol-defined instructions for method(s) of contraception.

Exclusion Criteria:

• Any acute or chronic medical illness.
• Active infection, including with coronavirus disease-19, diagnosed clinically by the investigator.
• History of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator or sponsor clinical trial physician, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.

Note: Other protocol-defined inclusion/exclusion criteria apply.